Prostate cancer prevention: Investigational approaches and opportunities

Cancer Research

Volumn 56, Issue 24, 1996, Pages 5547-5556

  Karp, Judith E ^a,b   Chiarodo, Andrew ^a   Brawley, Otis ^a   Kelloff, Gary J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 AZA 2' DEOXYCYTIDINE; ALPHA TOCOPHEROL; BICALUTAMIDE; CYTOKINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EXEMESTANE; FCE 28260; FENRETINIDE; FINASTERIDE; GENISTEIN; LIAROZOLE; LIPOXYGENASE INHIBITOR; MONOCLONAL ANTIBODY; OLTIPRAZ; PRASTERONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RETINOID; ROQUINIMEX; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; THALIDOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VITAMIN D DERIVATIVE;

CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; DRUG MECHANISM; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CELL DIVISION; CLINICAL TRIALS; DISEASE PROGRESSION; EPIDEMIOLOGY, MOLECULAR; GENES, RAS; HUMANS; MALE; MOLECULAR BIOLOGY; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RESEARCH; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0029753765     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. National Cancer Institute Division of Cancer Prevention and Control: Bethesda (MD): Cancer Statistics Review 1973-1992. NIH Publication No. 95-2789, 1995
2. Chiarodo, A National Cancer Institute roundtable on prostate cancer: future research directions. Cancer Res., 51: 2498-2505, 1991.
3. Kramer, B. S , Brown, M L., Prorok, P C , Potosky, A. L., and Gohagan, J. K Prostate cancer screening: what we know and what we need to know. Ann. Intern. Med., 119: 914-923, 1993
4. Potosky, A. L , Miller, B. A., Albertsen, P C , and Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer J Am. Med. Assoc., 273: 548-552, 1995.
5. Sakr, W A., Haas, G. P., Cassin, B F., Pontes, J. E , and Crissman, J. D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol., 150: 379-385, 1993.
6. Lippman, S. M., Benner, S. E., and Hong, W K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-873, 1994.
7. Hayes, R. B , Liff, J M., Pottern, L. M., Greenberg, R. S , Schoenberg, J. B., Schwartz, A. G., Swanson, G. M., Silverman, D. T., Brown, L. M., Hoover, R. N , and Fraumeni, J. F , Jr. Prostate cancer risk in U S blacks and whites with a family history of cancer Int. J Cancer, 60: 361-364, 1995.
8. Pienta, K J , and Esper, P S. Risk factors for prostate cancer. Ann. Intern Med., 118: 793-803, 1993.
9. Danley, K. L , Richardson, J. L., Bernstein, L., Langholz, B., and Ross, R K. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States) Cancer Causes Control, 6: 492-498, 1995.
10. Yu, H., Harris, R E , Gao, R , and Wynder, E. L. Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States Int. J. Epidemiol., 20: 76-81, 1991
11. Ziegler, R. G., Hoover, R N , Pike, M. C., Hildesheim, A., Nomura, A. M , and West, D W Migration patterns and breast cancer risk in Asian-American women. J. Natl. Cancer Inst , 85: 1819-1827, 1993.
12. Adlercreutz, H Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand. J. Clin Lab Invest , 50 (Suppl.): 3-23, 1990.
13. Adlercreutz, H., Markkanen, H., and Watanabe, S. Plasma concentrations of phytooestrogens in Japanese men Lancet, 342: 1209-1210, 1993.
14. Giovannuci, E., Rimm, E B , Colditz, G. A., Stampfer, M J , Ascherio, A., Chute, C C., and Willett, W. C. A prospective study of dietary fat and risk of prostate cancer J. Natl Cancer Inst., 85 1571-1579, 1993.
15. Hamalainen, E., Adlercreutz, H., Puska, P , and Pietinen, P. Diet and serum hormones in healthy men J. Steroid Biochem , 20: 459-464, 1984
16. Nomura, A M., and Kolonel, L. N. Prostate cancer, a current perspective. Epidemiol. Rev., 13: 200-227, 1991.
17. Pienta, K. J., and Esper, P. S. Is dietary fat a risk factor for prostate cancer? J. Natl. Cancer Inst., 85: 1538-1541, 1993
18. Grino, P. B., Griffin, J. E , and Wilson, J. D. Testosterone at high concentration interacts with the human androgen receptor similar to dihydrotestosterone. Endocrinology, 126: 1165-1172, 1988.
19. Montie, J. E , and Pienta, K. J Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 43: 892-899, 1994.
20. Ross, R. K., Bernstein, L., Lobo, R. A , Shimizu, H., Stanczyck, F. Z., Pike, M. C , and Henderson, B. E. 5-α-Reductase activity and risk of prostate cancer among Japanese and U. S white and black males. Lancet, 339: 887-889, 1992.
21. Fotsis, T., Pepper, M., Adlercreutz, H., Fleischmann, G., Hase, T , Montesano, R., and Schweigerer, L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad. Sci. USA, 90: 2690-2694, 1993
22. Henderson, B E., Ross, R. K , and Pike, M. C. Toward the primary prevention of cancer Science (Washington DC), 254: 1131-1138, 1991.
23. Whittemore, A S , Lee, C , Friedman, G. D., Stamey, T , Vogelman, J. H , and Orentreich. N Prostate-specific antigen as predictor or prostate cancer in black men and white men. J Natl Cancer Inst., 87, 354-360, 1995.
24. 24-18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun., 198 74-80, 1994.
25. Taplin, M-E., Bubley, G. J , Shuster, T D., Frantz, M E., Spooner, A. E , Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N. End. J. Med., 332 1393-1398, 1995
26. Visakorpi, T. Hyytinen, E., Koivisto, P., Tanner, M , Keinanen, R., Palmberg, C , Palotie, A., Tammela, T , Isola, J., and Kallioniemi, O-P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat. Genet., 9: 401-406, 1995.
27. Reichardt, J K V., Makridakis, N , Henderson, B. E., Yu, M. C., Pike, M. C , and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55 3973-3975, 1995
28. Irvine, R. A , Yu, M. C., Ross, R. K , and Coetzee, G. A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937-1940, 1995.
29. Carter, B. S., Beaty, T. H., Steinberg, G D., Childs, B., and Walsh, P. C Mendelian inheritance of familial prostate cancer Proc. Natl. Acad Sci. USA, 89 3367-3371, 1992.
30. Carter, B. S , Bova, G. S., Beaty, T. H., Steinberg, G. D , Childs, B , Isaacs, W. B , and Walsh, P. C. Hereditary prostate cancer: epidemiologic and clinical features. J Urol., 150: 797-802, 1993.
31. Bova, G. S., Carter, B. S., Bussemakers, M. J G., Emi, M., Fujiwara, Y., Kyprianou, N., Jacobs, S. C., Robinson, J. C., Epstein, J. I., Walsh, P C., and Isaacs, W. B. Homozygous deletion and frequent allelic loss of chromosome 8q22 loci in prostate cancer. Cancer Res., 53: 3869-3873, 1993
32. Cannon-Albright, L., and Eeles, R. Progress in prostate cancer Nat. Genet., 9: 336-338, 1995
33. Cher, M L., MacGrogan, D , Bookstein, R., Brown, J. A , Jenkins, R B., and Jensen, R. H. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer, 11: 153-162, 1994.
34. Eagle, L. R., Yin, X., Brothman, A R., Williams, B. J., Atkin, N. B., and Prochownik, E. V Mutation of the MXII gene in prostate cancer Nat. Genet., 9: 249-255, 1995.
35. Emmert-Buck, M. R., Vocke, C. D , Pozzatti, R. O., Duray, P. H., Jennings, S. B , Florence, C. D., Zhuang, Z., Bostwick, D. G , Liotta, L. A., and Linehan, W. M. Allelic loss on chromosome 8p12-21 in microdissected prostate intraepithelial neoplasia (PIN). Cancer Res., 55: 2959-2962, 1995
36. Gao, X., Zacharek, A., Salkowski, A., Grignon, D. J , Sakr, W., Porter, A T , and Honn, K. V. Loss of heterozygosity of the BRCAI and other loci on chromosome 17q in human prostate cancer. Cancer Res., 55: 1002-1005, 1995.
37. MacGrogan, D., Levy, A., Bostwick, D. G., Wagner, M , Wells, D., and Bookstein, R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 10: 151-159, 1994.
38. Trybus, T. M., Burgess, A. C., Wojno, K. J., Glover, T. W , and Macoska, J. A. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res., 56: 2263-2267, 1996.
39. Vocke, C., Pozzatti, R O., Bostwick, D. G., Florence, C D., Jennings, S. B., Strup, S., Duray, P. H , Liotta, L. A., Emmert-Buck, M. R., and Linehan, W M. Analysis of 99 microdissected prostate carcinomas reveals high frequency of allelic loss on chromosome 8p12-21. Cancer Res , 56: 2411-2416, 1996
40. Zhuang, Z., Bertheau, P., Emmert-Buck, M R., Liotta, L. A., Gnarra, J., Linehan, W. M., and Lubensky, I. A. A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am. J. Pathol , 146: 620-625, 1995.
41. Murphy, D. S., Hoare, S F , Going, J. J., Mallon, E. E A., George, W. D., Kaye, S B., Brown, R., Black, D. M., and Keith, W. N. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl. Cancer Inst , 87: 1694-1704, 1995.
42. Watson, P H., Safneck, J. R , Le, K., Dubik, D., and Shiu, R. P. C. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastases J. Natl Cancer Inst., 85 902-907, 1993
43. Korsmeyer, S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood, 80: 879-886, 1992
44. Colombel, M , Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A , Korsmeyer, S , and Buttyan, R Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J Pathol., 143 390-400, 1993.
45. Kim, N W., Piatyszek, M A., Prose, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G M , Wright, W. E , Weinrich, S L , and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 206: 2011-2015, 1994.
46. Rhyu, M. S. Telomeres, telomerase, and immortality. J. Natl. Cancer Inst., 87: 884-894, 1995.
47. Hayes, J. D., and Pulford, D. J. The glutathione-S-transferase supergene family, regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance Crit. Rev. Biochem Mol Biol., 30: 445-600, 1995
48. Perera, F P. Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J. Natl. Cancer Inst , 88: 496-509, 1996
49. Lee, W-H , Morton, R. A., Epstein, J. I., Brooks, J D., Campbell, P A., Bova, G. S., Hsieh, W-S., Isaacs, W B , and Nelson, W. G. Cytidine methylation of regulatory sequences near the pi class glutathione-S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad. Sci. USA, 91: 11733-11737, 1994.
50. Jutterman, R , Li, E , and Jaenisch, R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci USA, 91 11797-11801, 1994.
51. Morton, R. A., Ewing, C. M , Nagafuchi, A., Tsukita, S , and Isaacs, W B Reduction in E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res., 53: 3585-3590, 1993
52. Umbas, R , Isaacs, W. B , Bringuier, P P , Schaafsma, H. E , Karthaus, H. F. M , Oosterhof, G O. N , Debruyne, F. M. J., and Schalken, J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54 3929-3933, 1994.
53. Graff, J. R , Herman, J. G., Lapidus, R G., Chopra, H , Xu, R , Jarrad, D F., Isaacs, W B., Pitha, P. M., Davidson, N. E., and Baylin, S. E. E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55: 5195-5199, 1995
54. Ichikawa, T., Ichikawa, Y., Dong, J., Hawkins, A. L., Griffin, C. A , Isaacs, W. B., Oshimura, M., Barrett, J C., and Isaacs, J T Localization of metastasis suppressor gene(s) for prostate cancer to the short arm of human chromosome 11. Cancer Res., 52, 3486-3490, 1992.
55. Dong, J-T., Lamb, P W , Rinker-Schaeffer, C. W , Vukanovic, J., Ichikawa, T , Isaacs, J. T , and Barrett, J. C. KAII, a metastasis suppressor gene for prostate cancer on human chromosome 11p11 2. Science (Washington DC), 268: 884-886, 1995.
56. Jensen, R. A., Thompson, M. E., Jetton, T L , Szabo, C. I , van der Meer, R., Helou, B , Tronick, S R , Page, D. L. King, M-C., and Holt, J. T. BRCA1 is secreted and exhibits properties of a granin. Nat. Genet., 12: 303-308, 1996
57. Aaronson, S A. Growth factors and cancer Science (Washington DC), 254 1146-1153, 1991.
58. Gumbiner, B M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell, 84: 345-357, 1996.
59. Bostwick, D. G. c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role. J. Natl Cancer Inst., 86: 1108-1110, 1994.
60. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. Natl. Cancer Inst., 86: 1140-1145, 1994.
61. Ito, T , and May, W. S. Drug development train gathering steam. Nat. Med , 2: 403-404, 1996.
62. Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. Activation of raf as a result of recruitment to the plasma membrane Science (Washington DC), 264: 1463-1467, 1994.
63. Egan, S E., Giddings, B. W , Brooks, M W., Buday, L , Sizeland, A. M., and Weinberg, R. A Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation Nature (Lond.), 363: 45-51, 1993.
64. Li, N , Batzer, A , Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B , and Schlessmger, J. Guanine nucleotide-releasing factor hSos1 binds to Grb2 and links tyrosine kinases to Ras signalling. Nature (Lond.), 363: 85-88, 1993.
65. Rozakis-Adcock, M , Fernley, R., Wade, J., Pawson, T , and Bowtell, D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature (Lond ), 363: 83-85, 1993
66. Buday, L., and Downward, J. Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor Cell. 73: 611-620, 1993.
67. Gale, N W., Kaplan, S., Lowenstein, E J., Schlessinger, J., and Bar-Sagi, D. Grb2 mediates EGF-dependent activation of guanine nucleotide exchange on Ras. Nature (Lond.), 363, 88-92, 1993
68. ras. J. Biol. Chem., 51: 32621-32625, 1994.
69. Khosvari-Far, R., Cox, A. D , Kato, K., and Der, C. J. Protein prenylation: key to ras function and cancer intervention? Cell Growth & Differ , 3 461-469, 1992
70. Haag, J. D , Lindstrom, M. J , and Gould, M. N Limonene-induced regression of mammary carcinomas. Cancer Res , 52: 4021-4026, 1992.
71. James, G. L , Goldstein, J. L , Brown, M. S., Rawson, T. E. Somers, T. C, McDowell, R. S., Crowley, C. W., Lucas, B. K , Levinson, A. D., and Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science (Washington DC), 260, 1937-1942, 1993
72. Kohl, N. E. Mosser, S. D , deSolms, S J , Giuliani, E. A , Pompliano, D. L., Graham, S. L , Smith, R. L., Scolnick, E. M , Oliff, A., and Gibbs, J. B. Selective inhibition of ray-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 620: 1934-1937, 1993.
73. Kohl, N E., Omer, C. A , Conner, M. W , Anthony, N J., Davide, J. P., deSolms, S. J., Giuhani, E. A. Gomez, P. Graham, S. L , Hamilton, K., Handt, L. K , Hartman, G D , Koblan, K S , Kral , A M , Miller, P J , Mosser, S. D., O'Neill, T. J., Rands, E , Schaber, M D., Gibbs, J B., and Oliff. A Inhibition of farnesyl-transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med., 1: 792-797, 1995.
74. Grainger, D. J , and Metcalfe, J C. Tamoxifen: leaching an old drug new tricks? Nat. Med , 2: 381-385, 1996.
75. Roberts, A. B., and Sporn, M. B. Mechanistic interrelationships between two superfamilies the steroid/retinoid receptors and transforming growth factor-β Cancer Surv., 14: 205-220, 1992.
76. Wakefield, L M , and Sporn, M. B. Suppression of carcinogenesis, a role for TGF-β and related molecules in the prevention of cancer. In: G. Klein (ed ), Tumor Suppressor Genes, pp 217-243 New York: Marcel Dekker, Inc. 1990.
77. Butta, A., MacLennan, K , Flanders, K C , Sacks, N. P M., Smith, I., McKinna, A , Dowsett, M , Wakefield, L G., Sporn, M B., Baum, M , and Colletta, A. A. Induction of transforming growih factor β-1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res , 52: 4261-4254, 1992.
78. Glick, A. B., McCune, B. K , Abdulkarem, N., Flanders, K. C., Lumadue, J. A., Smith, J. M., and Sporn, M B Complex regulation of TGFβ expression by retinoic acid in the vitamin A deficient rat. Development (Camb.), 111: 1081-1086, 1991.
79. Egawa, S., Kadmon, D., Miller, G. J., Scardino, P T., and Thompson, T. C. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol. Carcinog., 5: 52-61, 1992
80. Lucia, M. S , Anzano, M. A., Slayter, M. V., Anver, M. R , Green, D. M , Shrader, M. W., Logsdon, D. L , Driver, C. L , Brown, C C., Peer, C. W., Roberts, A. B., and Sporn, M B. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinoma of the rat seminal vesicle and prostate. Cancer Res., 55: 5621-5627, 1995.
81. Pienta, K. J., Nguyen, N. M., and Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res., 53: 224-226, 1993.
82. Pollard, M , Luckert, P. H., and Sporn, M. B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide Cancer Res., 51: 3610-3611, 1991
83. Halgunsett, J., Sunde, A., and Lundmo, P. I. Retinoic acid (RA): an inhibitor of 5-α-reductase in human prostatic cancer cells. J. Steroid Biochem., 28: 731-736, 1987
84. Peehl, D. M., Wong, S. T., and Stamey, T. A. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate, 23, 69-78, 1993.
85. Giovannuci, E , Ascheno, A., Rimm, E. B., Stampfer, M. J., Colditz, G A., and Willett, W C Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl. Cancer Inst., 87, 1767-1776, 1995.
86. Dahiya, R., Park, H. D., Cusick, J., Vessella, R L , Fournier, G., and Narayan, P Inhibition of tumorigenic potential and prostate-specific antigen expression in LN-CaP human prostate cancer cell line by 13-cis-retinoic acid Int J. Cancer, 59: 126-132, 1994.
87. Smith, M. A., Parkinson, D. R., Cheson, B A , and Friedman, M. A. Retinoids in cancer therapy. J. Clin. Oncol., 10: 839-864, 1992.
88. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattam, M., and Willson, J. K V. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science (Washington DC), 268: 1336-1338, 1995.
89. Ivanovic, V., Melman, A , Davis-Joseph, B., Valcic, M., and Geliebter, J Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat. Med , 1: 282-284, 1995
90. Feldman, D., Skowronski, R. J , and Peehl, D. M. Vitamin D and prostate cancer Adv. Exp Med. Biol , 375: 53-63, 1995.
91. Peehl, D M., Skowronski, R. J., Leung, G. K., Wong, S. T , Stamey, T. A., and Feldman, D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res., 54: 805-810, 1994.
92. Skowronski, R J., Peehl, D. M., and Feldman, D. Actions of vitamin D3 analogs on human prostate cancer cell lines comparison with 1,25-dihydroxyvitamin D3. Endocrinology, 136: 20-26, 1995.
93. Studzinski, G. P., and Moore, D. C. Vitamin D and retardation of tumor progression. In: R R. Watson and S I. Mufti (eds ), Nutrition and Cancer Prevention, pp. 257-282. New York: CRC Press, 1996.
94. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
95. Vlodasky, I , Fuks, Z., Ishai-Michaeli, R., Bashkin, P., Levi, E., Korner, G , Bar-Shavit, R , and Klagsbrun, M. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J. Cell Biochem., 45: 167-176, 1991.
96. Folkman, J., and Ingber, D. Inhibition of angiogenesis. Semin. Cancer Biol., 3: 89-96, 1992.
97. Koch, A E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., and Strieter, R M. Interleukin-8 as a macrophage-derived mediator of angiogenesis Science (Washington DC), 258: 1798-1801, 1992.
98. Duling, B. R. Vascular endothelial growth factor (alias vascular permeability factor): a common link in neovascularization? News Physiol. Sci., 8: 144, 1993.
99. Plate, K. H., Breier, G., Weich, H A., and Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature (Lond.), 359: 845-848, 1992
100. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. Nature (Lond.), 359: 843-845, 1992.
101. Myers, C. E., Cooper, M , Stein, C , LaRocca, R , Walther, M. M., Weiss, G., Choyke, P., Dawson, N., Steinberg, S., Uhrich, M. M., Cassidy, J , Kohler, D. R., Trepel, J., and Linehan, W. M. Suramin: a novel growth factor antagonist with activity in hormone-refractory prostate cancer. J. Clin. Oncol , 10: 881-889, 1992.
102. Sartor, O., McLellan, C A., Myers, C. E , and Borner, M. M Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines J. Clin. Invest., 90: 2166-2174, 1992.
103. D'Amato, R. J., Loughnan, M S , Flynn, E., and Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci USA, 91: 4082-4085, 1994.
104. Vukanovic, J., Passaniti, A , Hirata, T , Traystman, R. J., Hartley-Asp, B., and Isaacs, J. T Antiangiogenic effects of the quinolone-3-carboxamide linomide. Cancer Res., 53: 1833-1837, 1993.
105. Vukanovic, J., Hartley-Asp, B , and Isaacs, J. T. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate, 26: 235-246, 1995
106. Joseph, I. B. J. K., Vukanovic, J., and Isaacs, J. T Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res., 56: 3404-3408, 1996
107. Vukanovic, J., and Isaacs, J. T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res., 55: 1499-1504, 1995.
108. 3 for angiogenesis Science (Washington DC), 264: 569-571, 1994.
109. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994
110. Crawford, E. D., Fair, W. R., Kelloff, G. J., Lieber, M. M., Miller, G. J., Scardino, P. T., and DeAntoni, E. P Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J. Cell. Biochem., 16H (Suppl.): 140-145, 1992
111. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Doody, L A Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem , 19 (Suppl.): 1-9, 1994.
112. Kelloff, G J., Johnson, J. R., Crowell, J. A., Boone, C W., DeGeorge, J. J., Steele, V. E , Mehta, M. U., Temeck, J. W., Schmidt, W. J., Burke, G., Greenwald, P., and Temple, R. J. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol., Biomarkers & Prev , 4: 1-10, 1995.
113. Williams, R D., Bostwick, D. G , Boone, C W., Catalona, W. J., McKeehan, W., and Thompson, I. M When is intervention warranted? J Cell. Biochem., 16H (Suppl ): 138-139, 1992
114. Kelloff, G. J., Boone, C W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res , 54 (Suppl.): 2015s-2024s, 1994
115. Geller, J. Effect of finasteride, a 5-α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J. Clin. Endocrinol Metab , 71: 1552-1555, 1990.
116. Tsukamoto, S., Akaza, H., Imada, S., Koiso, K., Shirai, T , Ideyama, Y , and Kudo, M. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J. Natl. Cancer Inst , 87: 842-843, 1995.
117. Gormley, G. J , Stoner, E , Bruskewitz, R. C , Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andnole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Bmkowitz, M. S., and Ng, J. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl J. Med., 327: 1185-1191, 1992.
118. Guess, H. A., Heyse, J. F., and Gormley, G. J. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate, 22: 31-37, 1993
119. Oesterling, J. E., Jacobsen, S. J , Klee, G. G., Pettersson, K., Piironen, T., Abrahamsson, P. A , Stenman, U. H., Dowell, B., Lovgren, T., and Lilja, H. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios J. Urol., 154: 1090-1095, 1995
120. Boone, C W., Kelloff, G. J , and Steele, V. E Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res , 52: 1651-1659, 1992.